This is criminal charge
sheet number 1 - a conspiracy to defraud Uncle Sam.
1.) The
“Enterprise” (a
RICO term) is the “American Lyme Disease Foundation.” Here we will refer
to them as “the Cabal.”
The testing for
Lyme disease was falsified to pass off fake vaccines and test kits for the
“Enterprise ”
Note: You are going to see a lot of redundancy in
these charge sheets. This is necessary because the crime is
multi-dimensional. We have to show what certain people did, how they did
it, and why they did it. There are CDC staff patent owners who publish
slander and libel, there are slanderers and libelers who also publish
scientifically valid biomarkers of nerve and brain degradation in Lyme
victims. There are people who play the Primers Shell Game but who also
published that the OspA vaccines cause immunosuppression and also slander
and libel their victims. There are people who assaulted Czech children with
a known fake Lyme vaccine that would do no good for Europeans, since there
is none of the American (Yale’s) LYMErix kind of OspA in Europe, who also
slander and libel.
In 1995 Yale’s Robert Schoen and Mayo Clinic’s David
Persing together worked on and published a method for the detection of “Lyme
disease” with a strain of Borrelia that had dropped the OspA-B plasmid
(PubMed, or PMID #
8968914) that Persing also patented (USPTO #
6,045,804). In that patent, Persing states that you can’t tell the
difference between late, “multi-system” Lyme and LYMErix injury (they both
essentially the same as post-septic shock). In the same patent, they state
that this testing method would be useful especially after LYMErix or an OspA
vaccine was on the market because it does not have the OspA-B plasmid, and
therefore it would not matter if the OspA or B antibodies were present and
come from a vaccinated person. One could just ignore those “primary,
immunodominant antigens.” If the test Borrelia strain does not have those
antigens and they show up in the Western Blot of a patient, one can discount
those antibodies and see if there are other bands present, which would mean
the person had been bitten by a tick and got Lyme. This was the reason
Steere committed research fraud in Europe to assure OspA and B would be left
out of the U. S. Center for Disease Control and Prevention’s (CDC’s)
diagnostic criteria for Lyme (which we call “Dearborn”).
The associated companies involved in this RICO-with-the-RICO, the ones
licensed to use this Post-LYMErix criminal method (Borrelia without the
OspA-B plasmid), were Persing’s new adjuvant company, Corixa, Yale’s L2
Diagnostics, and Imugen, in Norwood, MA. In other words, Steere falsified
the testing in Europe to assure that this RICO cabal would be the only
companies in North America (yes, they mentioned Canada, too) to be able to
receive blood for Vector Borne Diseases (VBDs) testing, and thereby have
access to all the new VBDs to ALSO patent. This whole
Dearborn scam was about an intended monopoly on testing and DNA products,
test kits and vaccines. Everything, the whole scam, depended on Yale’s
LYMErix vaccine being on the market. Obviously there will be a lot of
overlap in these chapters or charge sheets citing the citations and patents.
Etc. We hope the redundancy will also help with
learning about and understanding these crimes.
And, before we go any further, you want to meet the
World’s New Best Friend, OspA (or LYMErix, or Pam3Cys), because this
molecule given what it is/does, not only explains the Autism (brain damage
is the more correct term)-from-Vaccines-Pandemic, but why the U.S.
Government staff employees trashes, stalsk, harasses and denies all access
to care [Deprivation of Rights Under Color of Law], people with Chronic
Fatigue Syndrome, Lyme, Myalgic Encephalomyelitis, Fibromyalgia, Gulf War
Illness and so on with the “syndromes.”
Image from a hypotethetical HIV vaccine with Pam3Cys or
Tri-Palmitoyl Cysteine attached:
Int J Pept Protein Res. 1992
Sep-Oct;40(3-4):214-21.
A rational design of synthetic peptide vaccine
with a built-in adjuvant. A modular approach for unambiguity.
Defoort JP1, Nardelli
B, Huang
W, Tam
JP.
https://www.ncbi.nlm.nih.gov/pubmed/1478779
You can discover on your own that Pam3Cys is managed by TLRs 2 and 1, but we
will show many references here that prove this. Something that is
triacylated and managed by TLRs 2 and 1 could never have been and was never
a “vaccine.” It was the opposite, a fungal endotoxin more toxic than
lipopolysaccharide (LPS), a TLR4 agonist.
Chronology:
Originally, Lyme borrelia were perceived by the U. S.
Centers for Disease Control and Prevention (CDC) to be just another group of
Relapsing Fever organisms. Borreliae (the whole genus) undergo constant
antigenic variation, making vaccines and valid testing impossible except for
detection via an anti-flagellar antibody method. Chapter 5, the DNA
Primers Shell Game, explains more about the genetics.
At some point, it was decided by CDC officers that they should commercialize
Lyme and other emerging, tick-borne diseases by patenting vaccines and test
kits based on recombinant antigens, anyway. No one knows who gave the CDC
the authority to do this, but this decision coincided with the establishment
of the fake non-profit, the American Lyme Disease Foundation
(ALDF.com), Valhalla, NY, in 1990, by Edward McSweegan, Durland Fish, Gary
Wormser, and John J. Connolly, the then-president of New York Medical
College (NYMC) in association with Kaiser-Permanente (KP). KP is
still at NYMC writing MD-training modules. The CDC is often found in
collaboration with KP; we knew this even before their fake “Morgellon’s
investigation.”
The ALDF.com is a Government-Defrauding, Racketeering, and “Deprivation of
Rights under Color or Law” organization, where the wealthy “sponsors” were
apparently given some inside information regarding the companies that would
be manufacturing the bogus recombinant vaccines and test kits. Those
companies appeared to have been given some assurance against the prosecution
of the testing scam necessary to pass off these bogus recombinant products.
The Cabal, via changing the diagnostic standard, claimed Lyme was not just
another Relapsing Fever organism, but some entirely different disease. Yet,
spirochetes were for the last 100+ years known to be permanent brain and
lymph node infections, and that rodent brains used to be the formal storage
media (Barbour, 1986) before the CDC learned how to freeze-dry spirochetes
in 1964:
Microbiol Rev. 1986
Dec;50(4):381-400.
Biology of Borrelia
species.
Barbour AG, Hayes SF.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC373079/pdf/microrev00055-0033.pdf
And:
J Bacteriol. 1964
Sep;88:811.
RECOVERY OF TREPONEMA AND
BORRELIA AFTER LYOPHILIZATION.
HANSON AW, CANNEFAX
GR.
https://www.ncbi.nlm.nih.gov/pubmed/14208528
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC277387/pdf/jbacter00438-0287.pdf
Everyone will recall the Tuskegee “Bad Blood” experiment was
precisely about the dementia experienced by Caucasians as opposed to people
with an African background, while the “Enterprise” says Lyme borreliosis
(borrelia are more virulent than treponemes) cause only autoimmune arthritis
in a knee.:
Sex Transm Dis. 2014
Jul;41(7):440-6. doi: 10.1097/OLQ.0000000000000149.
Toll-like receptor polymorphisms are associated with increased neurosyphilis risk.
Marra CM1, Sahi
SK, Tantalo
LC, Ho
EL, Dunaway
SB, Jones
T, Hawn
TR.
"Clinicians in the early 20th century posited that race
influenced susceptibility to neurosyphilis, citing a decreased risk in
African Americans compared to Caucasians (7).
Subsequent work suggested a genetic basis for such differences, with an
increased risk of syphilitic dementia, but not other forms of neurosyphilis,
in patients with certain HLA types (8)
that differed in African Americans compared to Caucasians (9).
While more recent reports suggest that there may be genetic
contributions to syphilis susceptibility (10-13),
to the best of our knowledge there have been no recent investigations of
genetic susceptibility to neurosyphilis."
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414322/
More background or old news about borrelia:
Br Med J. 1911
Apr 1;1(2622):752.
THE INFECTIVE GRANULE IN CERTAIN PROTOZOAL INFECTIONS,
AS ILLUSTRATED BY
THE SPIROCHAETOSIS OF SUDANESE FOWLS.
Balfour A.
“AT the first meeting of the Tropical Medicine Section
of the British Medical Association in London last year I advanced the view
that, in all probability, what might be called the " infective granule"
would yet be found to play an important part in certain protozoal
infections, and more especially in spirochaetosis and trypanosomiasis. I
based this belief on the work of Leishman as regards the changes undergone
by Spirochaeta duttoniin Ornithodorus mioubata, and on the allied changes
which I had found to occur in the Sudan fowl spirochaete when ingested by
Argas per8icu. I have been continuing the work on fowl spirochaetosis and
have recently arrived a; some most interesting and significant results,
which may yet have considerable bearing on the view we must take of the
pathology of this and other spirochaetal diseases, and possibly also on
their treatment.
“The full account of these later researches will be presented in the
fourth report of these laboratories, which is now in the press, and is due
to appear in the autumn of the present year; here I wish merely to place on
record a few of the more salient features of the work.
“It will perhaps be remembered that one found intracorpuscular forms in
this fowl spirochaetosis, and that, following Sambon, one had come to the
conclusion that these endoglobular bodies represented a stage in the life.
cycle of the spirochaete-constituted, in short, its stage of schizogony in
the fowl. Sambon, however, who expressed this view from the study of a few
slides I gave him, did not indicate how this red cell invasion occurred. For
a long time I believed the spirochaetes themselves entered the red cells and
broke up, or coiled up, within them to form these remarkable bodies. As the
parasites can and do enter and leave the erythroblasts of the fowl, there
was good ground for this supposition. Now, however, I know better.
“By the use of the dark-field method, and more especially by practising
liver puncture on chicks at the crisis or on chicks which have been given a
sufficiently large dose of salvarsan, I have found that in the liver in
particular, also in the spleen and lung, the spirochaetes undergo an
astonishing change. They discharge from their periplastic sheaths spherical
granules, and it is apparently these granules which enter the red cells,
develop in them and complete a cycle of schizogony. The appearance is very
remarkable. If a well-infected chick be given a dose of salvarsan, the
peripheral blood is soon cleared, or nearly cleared, of spirocbaetes. If
then a drop of liver juice be examined by the dark-field method, it will be
found swarming with spirochaetes and with highly refractile granules. The
source of the latter is soon apparent, for attention will be directed to
spirochaetes which are not moving in the usual way, but are' in a state of
violent contortion, or are, so to speak, shaking themselves to and fro.
Indeed, I cannot give a more apt comparison than by likening their movements
to those of dogs which have been in water and are shaking themselves
vigorously to dry their coats. The object of the spirochaetes, however, is
to rid themselves of the bright, spherical granules which can be seen within
them, and which may or may not be aggregations of the so-called chromatin
core. These are forced along the periplastic sheath and suddenly discharged,
so that they become free in the medium and dance hither and thither as tiny,
solid, spherical, brilliantly white particles. In process of time the
spirochaete loses its activity, becomes difficult to see, and eventually all
that is left of it is the limp and lifeless sheath drifting aimlessly in the
fluid and liable to be caught up and swept away by some still vigorous
parasite. Such a sheath may still retain one or two of the granules which it
has been unable to discharge.
“As may be imagined, the process is most
fascinating to watch, and my observations have been confirmed by Captain Fry
and Mr. Buchanan, of these laboratories, and by Captain O'Farrell, R.A.M.C.
I may also say that the first-named had previously seen a shedding-off of
granules by trypanosomes in the peripheral blood of experimental animals, a
phenomenon which he is now -studying.
“It is these spirochaete granules in the liver,
spleen, and lung, and possibly also in other internal organs, which, I
believe, invade the red cells. I think I have seen the penetration occur,
but require to make further observations in order to be certain as to the
mode of entry. Such a chain of events fully explains all the puzzling
features which this intracorpuscular infection has hitherto presented, and,
moreover, brings it into line with the infective granules found in the
ticks, for these very closely resemble those seen in liver juice films both
when examined by the dark-field method and when stained by the Levaditi
process. There are various other pVints, more especially as regards the
peculiar staining reactions of these granules, into which I need not enter
beyond saying that the fact that, when free, they do not appear to take on
the Romanowsky stain may explain why they have not previously been noticed.
The work is also not yet complete, as it is necessary to find out if the
spirochaetes ingested by ticks behave in a similar manner and thereby
produce the granules of Leishman.
“I see that Jowett in South Africa has recently discovered what
appears to be an identical form of fowl spirochaetosis, and I trust he will
employ the dark-field method and endeavour by liver puncture and the use of
salvarsan, for the purpose of creating an artificial crisis, to follow out
the curious cycle I have indicated.
“From these observations and others which will be fuliy detailed at a
later date I have come to the conclusion that this fowl spirochaete must be
classed as a specific entity, and I am proposing for it the name
S.pirochaeta granulo8a penetrans, which, though lengthy, suitably indicates
its more important peculiarities. At the same time it is quite possible-nay,
even probable-that other pathogenic spirochaetes ehave in a similar manner.
I have found these granules to be resistant forms, and their presence in
countless num-bers in the tissues might explain part of the mechanism of
relapse and the difficulty of curing completely some of the more chronic
spirochaetal infections, as, for example, syphilis and yaws.
“In conclusion, I must thank Professor Ehrlich for most kindly placing at
my disposal an ample supply of his new and valuable remedy.”
https://www.ncbi.nlm.nih.gov/pubmed/20765548
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2333723/pdf/brmedj07824-0022.pdf
Recall now, if you aren’t recalling already, the
remarks of Willy Burgdorfer in the “Under Our Skin” movie interview that you
cant see borrelia in the blood, confirming the observations of 1911, above:
”Dr
Willy Burgdorfer granted and interview (which was supervised by staff from
the Rocky Mountain Laboratory,
National Institutes of Health, NIH). Excerpts from that interview,
concerning the circumstances of his discovery of the spirochetal agent of
Lyme borreliosis:
”Excerpt from an Interview with Dr Willy Burgdorfer;
”It was a ‘What in the hell? What’s in that smear?’ And then my work [on
relapsing fever] as a Swiss student came back. [I said to myself], ‘Willy,
these are spirochetes!’ The slide showed long slender forms, a little bit
curved, and they were only in the mid-part of the tick. Nowhere else. There
were so many people who said, ‘That is impossible Willie. You can’t get
spirochetes out of hard-bodied ticks.’ [But from my work on] relapsing fever
ticks from Africa, I knew what a spirochete looked like. The Belgian Congo
and Kenya are hotspots for relapsing fever. Even Livingston [the African
explorer and Scottish missionary] was exposed, and he called it ‘tick
fever.’
”’And [we] can’t even make a [blood] smear with Borrelia burgdorferi and see
the organism. It’s there. But you don’t see it. You cannot find this
spirochete. Why not? After all, I have a sick person here. He is trembling
all over. His synovial fluid is full of spirochetes. But when it comes to
blood, it’s not there. So there is something associated with this
organism that makes it different.” “
”Andy Wilson: ‘Why is Borrelia burgdorferi so hard to find in the body and
culture outside the body?’”
”Dr. Burgdorfer: ‘Borrelia burgdorferi in the tissues of a patient is
extremely difficult to demonstrate, because, first of all, you don’t like
somebody to take samples out of your brain [to look] for spirochetes. The
same with other tissues. Every system in your body can be infected with
spirochete. But to prove that is extremely difficult. It demands surgical
work, which is very expensive Andy Wilson: Are you a believer in the idea of
persistent Lyme infections? Dr. Burgdorfer: I am a believer in persistent
infections because people suffering with Lyme disease, ten or fifteen or
twenty years later, get sick [again]. Because it appears that this organism
has the ability to be sequestered in tissues and [it] is possible that it
could reappear, bringing back the clinical manifestations it caused in the
first place. These are controversial issues for microbiologists, as well as
the physicians who are asked to treat patients.’”
https://web.archive.org/web/20120814003829/http://www.underourskin.com/news/lyme-discoverer-willy-burgdorfer-breaks-silence-heated-controversy?page=1
So, spirochetes are there, you can’t kill
them, you can’t always see them, and they tend to hide out in the brain and
lymph nodes. See more on this in the Primers Shell Game chapter.
The American Lyme Disease Foundation, or ALDF.com
enterprise of intended Vector Borne Disease (VBDs) vaccine and test kit DNA
profiteers ( henceforth,“the Cabal”) changed the disease’s name to “Lyme
disease” from “Lyme borreliosis.” And yes, the participants in the scam
literally referred to themselves as an “enterprise” (Arthur Weinstein,
1998). They conspired to make Lyme relapsing fever even more
undetectable. Theirs was a 50-year roll out plan for DNA patented vaccines
and test kits due to the emerging tropic infections from global pollution.
Their first commercialized attempt at a recombinant DNA
product scam, with the toxic, fungal-ish (managed by Toll Like Receptors 2
and 1; TLR2/1) lipoprotein Outer Surface Protein A (OspA) was to vaccinate
~5000 people and send them out in the world to see if they got Lyme disease.
They then would test the people who became ill with a test that only detects
15% of the cases (the “Dearborn” “case definition”).
Their plan: make Lyme only 15% detectable so that the Cabal would be
guaranteed to have an at least 85% “effective” vaccine. If they
maliciously discredited the people who became ill as a result of the
“vaccine” itself (septic shock) or vaccine failure (Lyme), then the vaccine
would be “safe,” too. We call both the crime of falsifying the testing and
the resultant – and current – bogus testing criteria, “Dearborn.” This
slander and libel are “Deprivation of Rights via Color of Law” criminal
charges because the Cabal includes CDC officers Alan Barbour and Barbara
Johnson. You’ll read more about that event soon, here.
What was eventually discoverable with this scam was that the vaccine choice,
OspA (Pam3Cys or a tri-acylated lipoprotein), was a fungal antigen, a
TLR2/1-agonist, and as such caused immunosuppression in humans. It never
could have been a vaccine. Shed fungal antigens like OspA were the very
things responsible for the New Great Imitator outcomes.
In dogs, Gary Wormser saw the same immunosuppression
result with an OspA vaccine:
FEMS Immunol Med Microbiol. 2000
Jul;28(3):193-6.
Modulation of lymphocyte proliferative responses
by a canine Lyme disease vaccine of recombinant outer surface protein A
(OspA).
Chiao JW1, Villalon
P, Schwartz
I, Wormser
GP.
"OspA interferes with the response of lymphocytes to
proliferative stimuli including a blocking of cell cycle phase progression.”
http://www.ncbi.nlm.nih.gov/pubmed/10865170
The short version - and even the technical version -, is that OspA or a
triacyl lipopeptide or Pam3Cys gums up the immunity-works. This 2000 report
by Gary Wormser proves he knew Dearborn and OspA were false. Or “fraud.”
“Changed!!??” Yes, They Changed the Diagnostic
Standard for Lyme disease.
[Who said “Changed?!” Senator
Blumenthal’s 3 staff lawyers when I met with them in person in July 2003 and
showed them that the case definition changed at Dearborn, which no longer
defined Lyme as a relapsing fever organism, and which added the ELISA as a
sceen-out test for Chronic Neurologic Lyme. That was when they referred me
to Kevin J. Connor, the U.S. Attorney in Connecticut at the time, because
this was a federal case that crossed state lines.]
The following article by Allen Steere is the foundation of the CDC’s
original, fairly accurate and correct, 1990, “Lyme disease” “case
definition” blood test (serology). It was later thrown out and replaced at
a farce of a serology consensus conference put on by the CDC in 1994 in
Dearborn, MI.
J Clin Invest. 1986
Oct;78(4):934-9.
Antigens of Borrelia burgdorferi recognized
during Lyme
disease. Appearance of a new immunoglobulin M response and
expansion of the immunoglobulin G response late in the illness.
Craft JE, Fischer
DK, Shimamoto
GT, Steere AC.
“… Using immunoblots, we identified proteins of
Borrelia burgdorferi bound by IgM and IgG antibodies during Lyme disease. In
12 patients with early disease alone, both the IgM and IgG responses were
restricted primarily to a 41-kD antigen. This limited response disappeared
within several months. In contrast, among six patients with prolonged
illness, the IgM response to the 41-kD protein sometimes persisted for
months to years, and late in the illness during arthritis, a new IgM
response sometimes developed to a 34-kD component of the organism. The IgG
response in these patients appeared in a characteristic sequential pattern
over months to years to as many as 11 spirochetal antigens. The
appearance of a new IgM response and the expansion of the IgG response late
in the illness, and the lack of such responses in patients with early
disease alone, suggest that B. burgdorferi remains alive throughout the
illness.”
http://www.ncbi.nlm.nih.gov/pubmed/3531237
1990, CDC published this case definition based on the above:
ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/rr3913.pdf
“Laboratory criteria for diagnosis
”• Isolation of Borrelia burgdorferi from clinical specimen, or
“• Demonstration of diagnostic levels of IgM and IgG
antibodies to the spirochete in serum or CSF, or
”• Significant change in IgM and IgG antibody response to B. burgdorferi in
paired acute – and convalescent-phase serum samples.”
That means Lyme disease should be perceived as a relapsing fever organism,
undergoing antigenic variation. Victims are able to produce new, IgM bands
if the organism is still alive and not killed by antibiotics. This is a
well-known fact in immunology. New IgM bands mean the infection is ongoing.
Steere also wrote in the 1986 report that became the basis if these 1990
case definition that all you need is band 41 to diagnose Lyme; just rule out
syphilis. That is important to remember: You only need band 41, or the
anti-flagellar antibody and the triad of symptoms to diagnose Lyme with
common sense rule-outs. The U.S. patent #5,618,533 of Yale’s is for a
specific recombinant fragment of Borrelia burgdorferi flagellin. It is an
improvement on the band 41-only antibody test, and is an actual
FDA-validation according to the FDA’s criteria for the validation of an
analytical method (as shown in the Primers Shell Game criminal charge
sheet).
Before a diagnosis of Lyme, and of course in all illnesses, it is
recommended to rule out blood cancers. The symptoms of Chronic Lymphocytic
Leukemia are identical to chronic Lyme or Multiple Sclerosis (MS), not to
mention the fact that Lyme and LYMErix both are known to cause cancer, MS,
Lupus, and possibly Rheumatoid Athritis (RA) via the reactivation of latent
herpes viruses. Mycoplasma are also known to be associated with the
production of cancer and RA. Chronic, late, neurologic Lyme victims are
tolerized to these fungal type-, TLR2/1-agonist bearing diseases. The truth
about the “New Great Imitator” is that it is these other, secondary,
opportunistic herpes viruses and other bacterial/fungal infections are
responsible for that variety show of outcomes. It’s similar to AIDS. It is
mechanistically a form of Post-Sepsis Syndrome (“overwhelming the immune
system”).
This is the current, 1994,
CDC falsified, Dearborn case definition:
http://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm
“It was recommended that an IgM immunoblot be
considered positive if two of the following three bands are present: 24 kDa
(OspC)*, 39 kDa (BmpA), and 41 kDa (Fla) (1).
“It was further recommended that an IgG immunoblot be considered positive if
five of the following 10 bands are present: 18 kDa, 21 kDa (OspC)*, 28 kDa,
30 kDa, 39 kDa (BmpA), 41 kDa (Fla), 45 kDa, 58 kDa (not GroEL), 66 kDa, and
93 kDa (2).”
This 1994, current, diagnostic criteria are very different from the
1990 criteria and basically refer to only the late, HLA-linked, arthritis,
hypersensitivity response. It was developed via research fraud committed
by Allen Steere in Europe in 1992. OspA and B (bands 31 and 34) are notably
absent. Instead of only, now, having “the appearance of new IgM bands,”
which mean the infection or spirochetes was ongoing or the spirochetes were
still alive, we are now required to have the late, autoimmune Lyme arthritis
presentation in order to have a “case” of Lyme.
As an aside, we can assume that the reason the Cabal
did not want anyone treated for Lyme is because late in the disease, it’s
really about fungal antigen tolerance and cross tolerance, reactivated
herpes viruses, or is NIH’s incurable Post-Sepsis Syndrome. This outcome is
paralleled in many other conditions such as the failed Tuberculosis
vaccines, Malaria and Epstein-Barr resulting in Burkitt’s lymphoma, etc.
You’ll read more about that in later chapters.
Most recently (March 2015) the IDSA had this to say,
confirming our supposition:
PRACTICE MANAGEMENT
Infectious Diseases
Society of America 2014 Practice Guidelines To Diagnose, Manage Skin, Soft
Tissue Infections
The
Hospitalist.
2015 March;2015(3)
Author(s): Norihiro
Yogo, MD,
Carla C. Saveli, MD
"Likewise, the use of broad spectrum gram-negative
coverage is not recommended in most common, uncomplicated SSTIs and should
be reserved for special populations, such as those with immune compromise."
http://www.the-hospitalist.org/article/infectious-diseases-society-of-america-2014-practice-guidelines-to-diagnose-manage-skin-soft-tissue-infections/
Treatment of “Lyme” would allegedly compromise the
treatment of severe sepsis infections by creating an environment where those
secondary infections acquire antibiotic resistance genes from Lyme victims
being treated with the tougher antibiotics. The truth, however, is that
most infectious disease pathogens pick up resistance genes in swine
lagoons. Go ahead and look that up in the National Library of Medicine.
That should be well known by normal people. “Normal people” excludes this
Cabal and the Infectious Diseases Society of America (IDSA).
How Lyme or Borreliosis causes disease we learned from the OspA vaccine or
LYMErix fiasco. The fungal OspA vaccines caused the same “multi-system,”
“protean,” post-sepsis syndrome, chronic active infections/disease, as per
Ben Luft, Dave Persing, other scientists, and the vaccine victims themselves
as reported to the FDA through the VAERS. (You’ll see those links and
quotes, here in these chapters.) This is what we Lyme activists witnessed
in the first year LYMErix was on the market, early 1999. We said, “HOW are
these people saying they ‘have Lyme again?’ The vaccine wasn’t whole
spirochetes!” Later, we learned that the fact that the OspA vaccines was
giving victims the same “multi-system” disease, was already known to both
the Cabal and the U.S. Food and Drug Administions (FDA) committee members.
Follow: First, Lyme was a plain old regular Relapsing Fever organism
and the “New Great Imitator!" because it caused ALS, Lupus, MS, Cancer, RA,
stroke, etc.
Later, at the same time the crooks had a vaccine candidate in early phase
trials, it became nothing and a non-disease (psychiatric and hysteria and
other libel and slander, Barbour and Fish, 1993, etc.). We were then about
to get “a vaccine for a disease that causes no illness.”
This is still the current position of Yale, CDC, IDSA,
and the ALDF/EUCALB (EUCALB is the European counterpart of the criminal RICO
organization, the ALDF.com): “The Dearborn event was not real and not a
crime scene, Lyme patients are not sick, and OspA was a vaccine.” Every
time the Cabal makes a public claim about “Lyme disease” based on the
falsified Dearborn definition, that resets the clock on the Statute of
Limitations. Amusingly, IDSA and the Cabal are happy to say
what diseases are-not, but they never say what diseases
are. MD-America does not even notice that the CDC and the Cabal
appear to be insane, even after the FDA ordered LYMErix off the market in
February 2002 via ultimatum,… after Senator Richard Blumenthal (a former
USDOJ prosecutor) sued them for Anti-Trust, … after Edward McSweegan became
America’s infamous NIH employee as America’s one and only “Man With No Work”
(Google that), and even after Senators Markey, Blumenthal, et al, ordered
the FDA to assure Lyme testing was valid according to the FDA’s own
criteria. It’s really whacked that we have to be writing this for you, in
2017 - a hundred years since we knew what Relapsing Fever was about,
un-killable, goes to the lymph nodes and brain… blah, blah, white people get
dementia which was why the CDC performed 2 war crime bioweapons experiments
on American Blacks and Native Americans… It’s completely crazy that
99.9999% of Americans and all the “MDs” in America do not know what
spirochetes are and do.
The Not-Thinking and Not-Wondering may be an even more infamous
characteristic of Americans than our bioweapons-, and other war crimes.
----
Continuing the Chronology of Events in Redefining Lyme as a Non-Disease
to Pass Off a Bogus Vaccine:
1986, Edward McSweegan, in a fake whistleblower letter to Senator
Barry Goldwater, discredited the U.S. Navy to divert their vector borne
diseases funding to his ALDF.com cabal. See the Navy’s furious response in
the link below. McSweegan thinks there can be a vaccine for Relapsing Fever,
confirming the paraphysical theory that arrogance is the seed corn or
germinal element in true, genuine stupidity and/or the development of a
criminal mind:
http://www.actionlyme.org/GOLDWATER_LETTER.htm
1988, Raymond Dattwyler, JJ Halperin, et al, & immune-suppressing,
seronegative Lyme; supernatant (lipid layer) of borrelia mash causes NK cell
anergy or a blunted immune response. Later, Dattwyler tells the FDA Vaccine
committee that the seronegative patients are the sickest. Now we know why;
Lyme and LYMErix are the Great Detonators of the latent herpes viruses and
expanded or cross tolerance to other antigens than TLR2/1-agonist bearing
kinds; in short, they’re double-fatigued and neurologically damaged:
N Engl J Med. 1988
Dec 1;319(22):1441-6.
Seronegative Lyme
disease. Dissociation of specific T- and B-lymphocyte
responses to Borrelia burgdorferi.
Dattwyler RJ1, Volkman
DJ, Luft
BJ, Halperin
JJ, Thomas
J, Golightly
MG.
"We conclude that the presence of chronic Lyme disease
cannot be excluded by the absence of antibodies against B. burgdorferi and
that a specific T-cell blastogenic response to B. burgdorferi is evidence of
infection in seronegative patients with clinical indications of chronic Lyme
disease."
"The disorder in these seronegative patients reflected a dissociation
between T-cell and B-cell immune responses, in which the cell-mediated arm
of the immune response was intact yet the humoral portion of the immune
response to B. burgdorferi appeared to be blunted. This diminished antibody
response is in contrast to the T-cell anergy commonly observed in several
chronic infections (e.g., infection with Mycobacterium leprae or M. marinum,
filiarasis, and some chronic fungal infections (29-33)."
http://www.ncbi.nlm.nih.gov/pubmed/3054554
http://www.actionlyme.org/dattwyler1988_1.pdf
And:
Ann N Y Acad Sci. 1988;539:103-11.
Modulation of natural killer cell activity by
Borrelia burgdorferi.
Golightly M1, Thomas
J, Volkman
D, Dattwyler
R.
"Effect of B burgdorferi Culture on Normal PBL
”...when lymphocytes are cultured in the presence of growing Bb there is a
marked inhibition ( p < .0005 ) of NK activity on days 3, 5, and 7
when compared to lymphocytes cultured in BSKII media in the absence of
spirochetes. This effect is not due to a selective depletion or toxicity to
endogenous NK since viability studies and monoclonal antibodies demonstrate
no significant changes after culture with the organism.
"The inhibition is directly attributable to the organism or its
supernatants (data not shown)."
http://www.ncbi.nlm.nih.gov/pubmed/3056196
http://www.actionlyme.org/golightly_Datt1988.pdf
Perhaps the difference between the ”diminished antibody response is in
contrast to the T-cell anergy commonly observed in several chronic
infections (e.g., infection with Mycobacterium leprae or M. marinum,
filiarasis, and some chronic fungal infections (29-33)" and the B cell
incompetence in Borreliosis speaks to the fact that Borrelia like to go
directly to the lymph nodes as well as the brain. The lymph nodes are where
B cells mature or become specialized. This will be discussed later
(Baumgarth, et al).
1990, CDC: "Diagnose Lyme as if it was Relapsing Fever" as previously
mentioned.
ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/rr3913.pdf
1990, Allen Steere reports that "chronic, neurologic Lyme won't test
positive," uses Dattwyler and Volkman’s Seronegative Lyme T Cell Assay
N Engl J Med. 1990
Nov 22;323(21):1438-44.
Chronic neurologic
manifestations of Lyme disease.
Logigian EL1, Kaplan
RF, Steere AC.
"METHODS
”Neurological Evaluation…
”If the patient was seronegative according to these methods, the serum was
further tested by immunoblotting (25) and peripheral blood mononuclear cells
were tested for reactivity with borrelial antigens by proliferative assay.
(26)"
https://www.ncbi.nlm.nih.gov/pubmed/2172819
http://www.nejm.org/doi/pdf/10.1056/NEJM199011223232102
And what was reference number 26?
N Engl J Med. 1988
Dec 1;319(22):1441-6.
Seronegative Lyme
disease. Dissociation of specific T- and B-lymphocyte
responses to Borrelia burgdorferi.
Dattwyler RJ1, Volkman
DJ, Luft
BJ, Halperin
JJ, Thomas
J, Golightly
MG.
http://www.ncbi.nlm.nih.gov/pubmed/3054554
1990, ALDF.com founded-- a self-proclaimed “entrepreneurial” quartet,
includes Edward McSweegan, Durland Fish, Gary Wormser and John J.
Connolly. This evidence is in the office of U. S. Department of Justice
(USDOJ or DOJ) in New Haven, CT, USA on Church Street. It is a quote by
Arthur Weinstein in a publication the DOJ has been given (we no longer have
the link, just this:
http://www.actionlyme.org/CONNOLLY_FISH_WEINSTEIN.htm ).
1992, CDC officer Allen Steere falsifies testing in Europe:
The PubMed links to those 2 reports – no full text available, that is why I
got them out of the Yale Medical Library in 2002 and scanned them in are:
J Infect Dis. 1994
Feb;169(2):313-8.
Antibody responses to the three genomic groups of
Borrelia burgdorferi in European Lyme borreliosis.
Dressler F1, Ackermann
R, Steere AC.
http://www.ncbi.nlm.nih.gov/pubmed/8106763
http://www.actionlyme.org/dressler1994.pdf
J Infect Dis. 1993
Feb;167(2):392-400.
Western blotting in the serodiagnosis of Lyme
disease.
Dressler F1, Whalen
JA, Reinhardt
BN, Steere
AC.
http://www.ncbi.nlm.nih.gov/pubmed/8380611 , which is in full
text in the Dearborn booklet, downloadable here:
http://www.actionlyme.org/DEARBORN_PDF.pdf
Of those two reports of Steere’s lab shenanigans in Europe, only the second
one was made a part of CDC’s Dearborn booklet. The first one – the one left
out of the Dearborn booklet – is where you can see how he falsified the
testing for his later monopoly on post-LYMErix-approval for North America,
with Corixa, Yale’s L2 Diagnostics and Imugen. These 3 entities were
officially listed on the Securities and Exchange Commission (SEC) as
“partners” in sharing licensing of the RICO Monopoly patent with the strain
of Borrelia that had dropped an OspA-B plasmid under US Patent 6,045,804.
Steere, in Europe, used “high-passage” borreliae strains that drop
plasmids, and recombinant OspA and B without the lipids attached, helping
leave OspA and B out of the diagnostic standard (see the Dearborn
criteria above, there is no OspA or B, bands 31 and 34). The lipid parts of
the lipoprotein are known to be immune-stimulatory, or to produce
antibodies, so they obviously are necessary to come up with a legitimate
criteria.
Steere knew before the Dearborn event that people
without the arthritis HLAs were mostly seronegative against the fungal Osps:
Infect Immun. 1993
Jul;61(7):2774-9.
Association of treatment-resistant chronic Lyme arthritis
with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia
burgdorferi.
Kalish RA1, Leong
JM, Steere AC.
https://www.ncbi.nlm.nih.gov/pubmed/7685738
The Dearborn case definition says you
need 5 of 10 IgG bands (arthritis only), after the non-HLA-linked-,
non-arthritis cases are screened out in the first step, the ELISA.
That is, Chronic Neurologic Lyme cases, which are immunosuppression outcomes
- like AIDS, where the opportunistics do most of the damage and are what
keep you ill -, were left out at the first step, the ELISA, because
this outcome was caused by injections of the fungal toxin OspA (the Lyme
vaccines), too.
The Disease (fungal-toxic immunosuppression or post-sepsis
syndrome)…is the Cryme (saying OspA was a
“vaccine” when it caused the same toxic, post-sepsis syndrome). The
Dearborn case definition was not a consensus. The average accuracy was 15%,
as is shown in this booklet covering the Dearborn conference:
http://www.actionlyme.org/DEARBORN_PDF.pdf
The other, twin report by Steere in Europe left out of the Dearborn booklet:
J Infect Dis. 1994
Feb;169(2):313-8.
Antibody responses to the three genomic groups of
Borrelia burgdorferi in European Lyme borreliosis.
Dressler F1, Ackermann
R, Steere
AC.
.
https://www.ncbi.nlm.nih.gov/pubmed/8106763
What’s scientific fraud about this ”Antibody Responses in Europe”
report?
1) Allen Steere in the IgM ELISA arbitrarily raised the "noise"
cutoff of 3 standard deviations to 5 std dev (3 is normally done) such that
most Neurologic cases would be missed (arthritis cases produce lower IgM,
for some reason).
2) Steere in the IgG-falsification step, averaged the concentration of IgGs
from the meningitis or neurologic Lyme (lower, like 1:400 dilution), with
acrodermatitis (autoimmune, very high antibody concentration of about
1:25o0) and arthritis (1:800 dilution).
This fraud deliberately excluded the sickest patients in the first step of
the Dearborn "2-tiered" testing criteria for Lyme. Note that it is strange
that Steere felt he had to develop this new Dearborn panel in Europe,
presumably where American Justice would have a hard time verifying the data.
Note this same report reveals an intended a later monopoly on testing for
Lyme once the bogus OspA vaccines were on the market (you never test for a
disease with the same antigens that are the vaccine antigens since you would
not know if the antibodies are from the actual infection or from the vaccine
antigens):
The above graphic from the same report shows:
3) Steere used high passage strains which lose plasmids and therefore
potential antigens (meaning if you have those antibodies, they wont
be detected).
4) Steere used strain B31 which essentially does not have the European kinds
of OspAs, and
he assured no one would have antibodies against OspA and B in this Dearborn
antibody panel for Western Blotting by leaving off the Pam3 or the tri-acyl
or the lipid groups of these triacyl lipoproteins which cause antibodies.
The protein ends by themselves are not immunogenic (cause antibodies to be
produced).
The following is the text (not in the abstract) of what is in the report on
exactly how Steere defrauded the U.S. Government and people:
J Infect Dis. 1994
Feb;169(2):313-8.
Antibody responses to the three genomic groups of
Borrelia burgdorferi in European Lyme borreliosis.
Dressler F1, Ackermann
R, Steere
AC.
“The group 1 strain of B. burgdorferi, G39/40, used in this study and in
the previous study of US patients was isolated from an Ixodes dammini tick
in Guilford, Connecticut [21]. The group 2 strain, FRG [Federal Republic of
Germany], was isolated from Ixodes ricinus near Cologne [22]. The group 3
strain, IP3, was isolated from Ixodes persulcatus near Leningrad [23]. All
three strains used in this study were high passage isolates, which were
classified by Richard Marconi (Rocky Mountain Laboratory, Hamilton, MT)
using 16S ribosomal RNA sequence determination as described [11, 24]. The
recombinant preparations of OspA and OspB used in this study were purified
maltose-binding protein-Osp fusion proteins derived from group 1 strain B31
[25]. The fusion proteins contained the full-length OspA or OspB sequence
without the lipid moiety or the signal sequence…"
http://www.ncbi.nlm.nih.gov/pubmed/8106763
He left the OspA (band 31) and OspB (band 34) out, deliberately.
The following is what it says in the Persing/Schoen/Steere or Imugen RICO
Monopoly patent, that shows the intended monopoly - which required that OspA
and B be missing from the diagnostic panel and from the spirochetes used to
test the human population after the population was vaccinated with OspA:
Method for detecting B. burgdorferi infection
"…Additional uncertainty may arise if the vaccines are not completely
protective; vaccinated patients with multisystem complaints characteristic
of later presentations of Lyme disease may be difficult to distinguish from
patients with vaccine failure."
and
"The present invention provides a method useful to
detect a B. burgdorferi infection in a subject. The method provided by the
invention is particularly useful to discriminate B. burgdorferi infection
from OspA vaccination, although it is sufficiently sensitive and specific to
use in any general Lyme disease screening or diagnostic application. Thus,
the method of the invention is particularly appropriate for large scale
screening or diagnostic applications where only part of the subject
population has been vaccinated or where the vaccination status of the
population is unknown. "
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
The monopoly on post-LYMErix-FDA-approval testing for all vector borne
diseases in America and Canada was their stated intention (entrepreneurial
or enterprise = RICO). Once LYMErix was on the market, a strain of borreliae
that did not have the vaccine antigens in it would have to be used for
testing for “Lyme.” Vaccine efficacy is never assessed with the very same
antigen as the vaccine antigen. Otherwise, it would not be known if the
victim has the actual infection in question, or that the antibody that shows
up came from the vaccine. This Lyme/Vector-Borne Diseases monopoly depended
on LYMErix being on the market. That way, Corixa, L2 Diagnostics and Imugen
would be the only labs in the country licensed to use this RICO strain. They
would have access to all the human blood to pharm all sorts of DNA data to
patent from humans as well as any new and emerging infectious diseases. That
was the monopoly: LYMErix and the bogus testing criteria together with
Persing’s RICO patent had the intention of gathering all the blood, and all
the potential infections in that blood, and what mean meant even more
vaccine patents in the future would go to this Cabal. The three, Corixa,
Imugen and Yale’s L2 Diagnostics, listed themselves as “partners” in a
Securities and Exchange Commission announcement and advertised that this
test would be available for the vaccinated population.
The Cabal falsified the “case definition” to leave out neurologic Lyme
cases, and they left OspA and B out for a later monopoly on testing and
future patents. And there, you just read that that intention is clearly
stated in a patent and method developed by Schoen and Persing in 1995 (US
patent 6,045,804), next:
J Clin Microbiol. 1997
Jan;35(1):233-8.
Borrelia burgdorferi enzyme-linked immunosorbent
assay for discrimination of OspA vaccination from spirochete infection.
Zhang YQ1, Mathiesen
D, Kolbert
CP, Anderson
J, Schoen
RT, Fikrig
E, Persing
DH.
http://www.ncbi.nlm.nih.gov/pubmed/8968914
Whose name do you see there, with Persings? Right, Yale’s Robert
Schoen’s. Therefore he knew that there was a problem with LYMErix and that
an opportunity was presented by patenting this bug with the no-OspA/B
plasmid in it: a monopoly on all future vaccines and test kits for vector
borne diseases (VBDs).
1992, CDC staff, Barbara Johnson and Joe Piesman, own patents with
SmithKline that show 2 kinds of Lyme, HLA-linked and non-HLA-linked
antigens:
COMPOSITIONS USEFUL IN DIAGNOSIS AND
PROPHYLAXIS OF LYME DISEASE
"Summary of the Invention
"In one aspect, the invention provides isolated B. burgdorferi antigens
which are regulated and differentiated by growth of the B. burgdorferi in a
tick vector. Novel antigens of the invention are listed below in Table I.
"Certain of these antigens are characterized as being B. burgdorferi B31
strain specific and major histocompatibility complex (MHC) nonrestricted.
Certain other of these antigens are characterized as being MHC-restricted."
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19931209&CC=WO&NR=9324145A1&KC=A1
Why is the CDC talking about ”MHC-restricted” vs. “MHC
non-restricted?”
What we know that to mean is that classic “autoimmune” diseases tend to be
MHC-(or HLA-) restricted, or the antigens, due to intermolecular forces,
either bind in the HLA groove too strongly, the HLA-antigen complex is
released as yet another free, new antigen, or the antigen does NOT bind
tightly enough and the antigen falls out of the HLA groove to re-stimulate.
This “autoimmune” only is the new definition Steere claimed in these 1992
reports and at the CDC’s 1994 Dearborn conference. He falsely claimed Lyme
disease is only the HLA- or MHC-arthritis-restricted and threw out the
other, meningitis cases.
Yet, here, in their 1992 patents with SmithKline, the CDC mentions the other
outcome-- the no- or fewer- antibody result. Therefore, they recognize the
two kinds of Lyme: the 15% of the population with the Rheumatoid Arthritis
genegtic background or HLA-restricted or arthritis cases,… and the 85% with
seronegative, neurologic, long term, New Great Imitator Lyme.
The 85% of the chronic disease sufferers most likely suffer from the
opportunistics (NIH’s “Post-Sepsis Syndrome”) from the imunosuppression that
is caused by shed Borrelial TLR2/1-agonist antigens. Regardless, the
falsified tests result in more early Lyme cases going undiagnosed and
therefore progressing to permanent disability and early death.
1993, Barbour and Fish slam Neurologic Lyme victims in:
Science. 1993
Jun 11;260(5114):1610-6.
The biological and social phenomenon of Lyme
disease.
Barbour AG1, Fish
D.
https://www.ncbi.nlm.nih.gov/pubmed/8503006
Barbour and Fish admit in this report that Phase I and Phase II trials
of OspA vaccines are underway. Therefore, as is shown in the Persing RICO
Monopoly patent (US 6,045,804), they already knew the OspA vaccines were
causing a disease indistinguishable from vaccine failure, or CHRONIC LYME:
Here would be a good place to show what data was received by the USDOJ in
New Haven, CT, on this fraud and RICO scam, because the difference between
neurologic Lyme and arthritis Lyme is so clear:
Compare the blots from the two kinds of Lyme in this (above) July 2003 RICO
complaint. On the left with the faint antibody bands is neurological Lyme
(the sickest, according to Ray Dattwyler), and on the right are the
HLA-linked outcomes of arthritis and acrodermatitis:
http://www.actionlyme.org/USDOJ_COMPLAINT_RICO.htm
Hence, the Cabal left out the neurological outcomes in
their Dearborn scam. The whole point of the redefinition of Lyme at Dearborn
was to narrow it to just the HLA-linked, arthritis, supposedly autoimmune,
hypersensitivity cases. This is how and why they get away with perjury. When
the IDSA/Yale Lyme Cabal say “Lyme Disease,” they mean exclusively
“HLA-linked arthritis AND NO OTHER SYMPTOMS.” No lawyer was or is aware of
this semantics scam.
Jump to 2005; Here Klempner and Wormser re-revealed that “Lyme disease” is just
one thing: a bad knee and no other illness signs. However, as shown
above, there are two distinct outcomes of Lyme borreliosis. The
controversial one (neurologic-, chronic fatigue- Lyme) really does not have
a name right now. Therefore, “Lyme disease” is defined as ONLY a bad knee.
It’s a legal definition. It’s also criminal one, based on fraud and no
consensus, but here is what it is again (2005):
J Infect Dis. 2005
Sep 15;192(6):1010-3. Epub 2005 Aug 4.
A case-control study to examine HLA haplotype associations in patients with posttreatment chronicLyme disease.
Klempner MS1, Wormser
GH, Wade
K, Trevino
RP, Tang
J, Kaslow
RA, Schmid
C.
”… There appear to be at least 2 distinct syndromes after antibiotic
treatment. [They have no data on un-treated people, obviously, since they
could not ethically conduct such a study-KMD] One syndrome has localized
symptoms that are similar to pretreatment symptoms. Patients with this
syndrome often have recurrent episodes of arthritis/synovitis. Results of
synovial fluid cultures and polymerase chain reaction (PCR) for B.
burgdorferi are generally negative…. [See
the DNA/RNA Shell Game report, this is not true http://www.actionlyme.org/PRIMERSHELLGAME.htm ;
it’s a shell game; they use DNA that they know won’t be there in that
sequence due to antigenic variation to claim “No Lyme here.”-- KMD]
“…Patients generally feel well aside from their arthritis symptoms.”
https://www.ncbi.nlm.nih.gov/pubmed/16107953
http://jid.oxfordjournals.org/content/192/6/1010.full
Let’s restate what Wormser and Klempner are trying to say in that 2005
report:
”The people with the falsified Dearborn case definition of ‘only an
HLA-linked arthritis in a knee’ have only an HLA-linked arthritis in a knee
and no other symptoms.”
If you falsify the case definition and say “ONLY the HLA-linked
hypersensitivity response of bad knee can be a ‘case’ of ‘Lyme disease,’"
you can then, 11 years later say, “Oh, how amazing for us to find only the
HLA-linked case definition of arthritis-only is an HLA-linked
arthritis-only, and is only a bad knee.“
These people are crazy, yes, if that is what you were thinking.
Also, the CDC recently reacted to the Senators'
(Blumenthal, Markey, et al) letter to the Office of Policy and Management,
where the Senators are forcing the FDA to do their jobs and assure that the
testing for Lyme is validated according to their own FDA rules. (See the
Primers Shell Game for more on that.) The CDC is trying to say that the
Dearborn method was FDA validated, when it was not:
”Washington – Senator Edward J. Markey (D-Mass.) was joined by Senators
Richard Blumenthal (D-Conn.), Elizabeth Warren (D-Mass.), Sherrod Brown
(D-Ohio), and Dick Durbin (D-Ill.) in calling on the Obama administration to
release draft guidance to ensure appropriate oversight of laboratory
developed diagnostic tests (LDTs), which are used to help diagnose specific
forms of cancer and other diseases and are not approved by the Food and Drug
Administration (FDA). Laboratories initially manufactured LDTs that could be
used for low-risk diagnostics or for rare diseases, but with new technology,
they have become a staple of clinical decision-making and are being used to
diagnose high-risk but relatively common diseases such as ovarian cancer.
Recently, the Centers for Disease Control and Prevention (CDC) reviewed a
frequently utilized LDT to detect Lyme disease and found “serious concerns”
about false-positive results and misdiagnosis. The CDC recommended that the
diagnosis of Lyme disease should instead be left to tests approved by the
FDA. ...”
http://politicalnews.me/?id=29174&keys=DIAGNOSES-CONDITIONS-MEDICAL-OBAMACARE
Here are the FDA’s rules for the validation of an analytical method:
which were met by Yale’s 1991 Flagellin Method Patent US # 5,618,533 and
this report:
Infect Immun. 1991
Oct;59(10):3531-5.
Molecular characterization of the humoral
response to the 41-kilodalton flagellar antigen of Borrelia burgdorferi, the Lyme disease agent.
Berland R1, Fikrig
E, Rahn
D, Hardin
J, Flavell
RA.
”The earliest humoral response in
patients infected with Borrelia burgdorferi, the agent of Lyme disease, is
directed against the spirochete's 41-kDa flagellar antigen. In order to map
the epitopes recognized on this antigen, 11 overlapping fragments spanning
the flagellin gene were cloned by polymerase chain reaction and inserted
into an Escherichia coli expression vector which directed their expression
as fusion proteins containing glutathione S-transferase at the N terminus
and a flagellin fragment at the C terminus. Affinity-purified fusion
proteins were assayed for reactivity on Western blots (immunoblots) with
sera from patients with late-stage Lyme disease. The same immunodominant
domain was bound by sera from 17 of 18 patients. This domain (comprising
amino acids 197 to 241) does not share significant homology with other
bacterial flagellins and therefore may be useful in serological testing for
Lyme disease.” http://www.ncbi.nlm.nih.gov/pubmed/1894359
As you can see, the FDA has not changed their rules on how to validate a
method:
”Under the FD&C Act, the FDA assures both the analytical validity (e.g.,
analytical specificity and sensitivity, accuracy and precision) and clinical
validity through its premarket clearance and approval process.”
http://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407409.pdf
Also, Borrelia burgdorferi is closest genetically to B. anserina, an African
bird borreliosis, so it is not surprising that Lyme is found all across the
United States, being carried by birds:
Many California bird species host the Lyme
disease bacterium, study finds:
http://www.latimes.com/science/sciencenow/la-sci-sn-california-birds-lyme-disease-20150225-story.html
See more on the the phylogeny or the genetics that shows Lyme is closest to
B. anserina (from Africa) in the DNA Shell Game document. Therefore there
cannot be any “disease calculator” for Lyme as there fraudulently had been
in the past, in an attempt to limit diagnoses. Just as all kinds of
Borreliae are everywhere, so is this specific one, burgdorferi.
Returning to the Chronology of the Crime
1994, June; FDA LYMErix Meeting (note that June precedes
October--when the Dearborn stunt took place-- so the FDA never approved of
the Dearborn method, not to mention it was research fraud, and not a
consensus):http://www.actionlyme.org/1994_FDA_MEETING_LYMERIX.htm
Transcript of June 1994 FDA Meeting Minutes on Lyme and potential vaccines:
Dr.O’BRIEN: “I was
concerned about your last slide where you said there was a poor correlation
between serologic response and clinical disease. And as I heard you to say,
some people who mount better immune responses get worse disease. Did I hear
you say that?”
DR. DATTWYLER: “No, no, I said the reverse. The better responses tended to
have better response. And I should clarify where this is from. This is from
antibiotic trials. These are treatment trials of erythema migrans, in which
individuals given an antibiotic regimen which was not optimal – we did not
know that it was not optimal at the time – the ones that failed to mount a
vigorous response tended to do worse, clinically. So, there was an inverse
correlation between the degree of serologic response and the outcome.”
“So, individuals with a
poor immune response tend to have worse disease."
We know why, now, that “individuals with a poor
antibody response have worse disease.” Borrelial fungal antigens cause
immunosuppression and a classic post-sepsis-like result with chronic active
EBV, HHV-6, et al. And we know this is not just from antibiotic treatment as
Dattwyler said at this FDA meeting--that the diminished responses are due to
the organism or its supernatants, like OspA, and that that is typical for
fungal infections:
N Engl J Med. 1988
Dec 1;319(22):1441-6.
Seronegative Lyme
disease. Dissociation of specific T- and B-lymphocyte
responses to Borrelia burgdorferi.
Dattwyler RJ1, Volkman
DJ, Luft
BJ, Halperin
JJ, Thomas
J, Golightly
MG.
”We conclude that the presence of chronic Lyme disease
cannot be excluded by the absence of antibodies against B. burgdorferi and
that a specific T-cell blastogenic response to B. burgdorferi is evidence of
infection in seronegative patients with clinical indications of chronic Lyme
disease.”
”The disorder in these seronegative patients reflected a dissociation
between T-cell and B-cell immune responses, in which the cell-mediated arm
of the immune response was intact yet the humoral portion of the immune
response to B. burgdorferi appeared to be blunted. This diminished antibody
response is in contrast to the T-cell anergy commonly observed in several
chronic infections (e.g., infection with Mycobacterium leprae or M. marinum,
filiarasis, and some chronic fungal infections (29-33).”
http://www.ncbi.nlm.nih.gov/pubmed/3054554
http://www.actionlyme.org/dattwyler1988_1.pdf
And (1988):
Ann N Y Acad Sci. 1988;539:103-11.
Modulation of natural killer cell activity by
Borrelia burgdorferi.
Golightly M1, Thomas
J, Volkman
D, Dattwyler
R.
"Effect of B burgdorferi Culture on Normal PBL
"...when lymphocytes are cultured in the presence of growing Bb there is
a marked inhibition ( p < .0005 ) of NK activity on days 3, 5, and 7 when
compared to lymphocytes cultured in BSKII media in the absence of
spirochetes. This effect is not due to a selective depletion or toxicity to
endogenous NK since viability studies and monoclonal antibodies demonstrate
no significant changes after culture with the organism.
"The inhibition is directly attributable to the organism or its supernatants
(data not shown)."
http://www.ncbi.nlm.nih.gov/pubmed/3056196
The diminution of antibody response is might be instead due to the fungal
antigens shed by Borrelia and not antibiotics since this phenomenon is seen
in parallel in other human fungal-exposure immunology. See those other
scientific examples, including from the CDC on the failed Autism vaccines
and the failed Tuberculosis vaccines, here: http://www.actionlyme.org/SASH_POLICYPAPER_MECFS.htm
1994, CDC's invitation to participate in the Dearborn event. Labs
were invited; they said the Steere proposal was only, on average, 15%
accurate; CDC then blew off these labs’ recommendations:
http://www.actionlyme.org/DEARBORNINVITATION.pdf
1994, October; CDC's Dearborn Booklet .pdf
http://www.actionlyme.org/DEARBORN_PDF.pdf
1994 - Dearborn, Who Said What (also
summarized for the FDA at their Jan 2001 hearing on adverse events to
LYMErix): http://www.actionlyme.org/DEARBORN_WHO_SAID_WHAT.htm
1) Gary Wormser at New York Medical College reports that Steere’s Dearborn
proposal method detected 9/59 of IgG cases or is 15% accurate, missing 85%
of the cases:
J Clin Microbiol. 1993
Dec;31(12):3090-5.
Serodiagnosis in early Lyme
disease.
Aguero-Rosenfeld ME1, Nowakowski
J, McKenna
DF, Carbonaro
CA, Wormser GP.
”Overall, 51 of 59 (86%) convalescent phase serum specimens were
reactive by IB [Dearborn criteria Immunoblot-SASH], 35 of which were
interpreted as positive; 26 based on IgM criteria, 8 based on both IgM and
IgG, and 1 based on IgG criteria…”
https://www.ncbi.nlm.nih.gov/pubmed/8308100
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC266355/pdf/jcm00024-0026.pdf
That is, according to Gary Wormser, 9 out of 59 cases were positive to
Dearborn later in the disease; Gary Wormser assessing Steere’s Dearborn
panel proposal in this report, says it only detects 15% of the cases in IgG.
Other’s at Dearborn said…
2) Igenex —Steere’s IgG panel detected 8% of the cases
3) Imugen —Steere’s IgG panel detected 14% of the cases
4) Wisconsin —Steere’s method was 15% accurate
5) UCONN —Larry Zemel was referring to Lyme as comparable to only juvenile
rheumatoid arthritis when of course it isn’t. Recommended adding band 50 for
children’s blots.
6) Roche— 28% were positive for 5 of 10 Steere IgG bands.
7) Wadsworth— had some different scoring system. Did not report on accuracy
of Steere's method
8) Ontario Ministry of Health—did not give an assessment of the Steere
proposal (page 86)
9) Lutheran Hospital— 22% were accurate by Steere’s IgG
10) MarDx Labs— recommended adding bands 31 and 34, but were given CDC
positive arthritis positive blood to falsely qualify their test strips.
Their Western Blot test strips were used in both OspA vaccine trials. MarDx
was later sold to an Irish company, Trinity Biotech, Dublin; all the data
they had about this crime was taken out of the country.
11) CDC Atlanta— talked about mice, not humans. The mouse criteria was 2 out
of three from OspC, 16 kD, 17.9 kD, for the mice.
We got this standard anyway, even though none of the invited participants
agreed - not by a long shot.
See the Primers Shell Game for an explanation of how VALID testing is
performed according to the FDA rules, and how Yale knows all about how to
validate a method for Lyme (Bb-specific flagellar antigen) and patented it
(US 5,618,533). This is all obvious criminal fraud. Yale owned a valid test
for Lyme but did not use it to qualify their other patented product, rOspA,
LYMErix.
Who was involved with approving the bogus Dearborn method at Dearborn when
all the invited labs said it was only 15% accurate (and FDA criterion for
validation)?
None other than the CDC vaccine patent owners and all the scammers you see
here: http://www.actionlyme.org/Dearborn_Who_Approved.htm
“Alan Barbour,” “Edward McSweegan,” “Allen Steere,”
“Arthur Weinstein,” "The CDC Lyme Disease Group" (Barbara Johnson), etc.
(The same people involved in the OspA vaccines scam were involved in
falsifying the testing and who were the original members and “advisors” of
the ALDF.com.)
A view of the Dearborn event by a participant. It’s an independent paper
about it; Igenex’s Nick Harris’ report published in the Lyme Disease
Foundation’s journal:
http://www.actionlyme.org/HARRIS_IGENEX_DEARBORN.pdf
Evidence Lyme Cabal knew LYMErix produced the same
"multisystem disease" as "Chronic Lyme"
1) Ben Luft said it at the 1998 FDA meeting:
http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3422t1.rtf
BEN LUFT: "The point that I wanted to make in regard to
the study is that there is very heavy dependence on serologic confirmation.
And when we start thinking about the adverse events, *** it was stated
originally when we got the overview of the disease that the disease is
really quite protean. And actually the adverse events are very similar to
what the disease manifestations are.**** And if you start to, as I think Dr.
Hall was eluding to -- if you start to kind of say well how often do you
actually become seropositive, you can start to have a different take on when
someone has an adverse event or whether it is disease specific or infection
specific versus vaccine specific. And I think that that is an important
issue that we have to deal with. ..."
2) Dave Persing said it in his RICO patent (above),
Method for detecting B. burgdorferi infection
"…Additional uncertainty may arise if the vaccines are not
completely protective; vaccinated patients with multisystem complaints
characteristic of later presentations of Lyme disease may be difficult to
distinguish from patients with vaccine failure."
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
3) Fish and Barbour trashed Lyme disease victims with their “Social Aspects”
report in 1993 (above), paving the way to slander and libel their future
LYMErix victims. They reveal that the OspA vaccine trials are underway in
that report. This shows intent to cause harm:
Science. 1993
Jun 11;260(5114):1610-6.
The biological and social phenomenon of Lyme
disease.
Barbour AG1, Fish
D.
https://www.ncbi.nlm.nih.gov/pubmed/8503006 http://actionlyme.org/BarbourFishpdf.pdf
4) Dave Persing (who worked on this with Robert Schoen, as shown above) and
his company Corixa wanted to sell vaccine adjuvants, but they had to drop
OspA as a candidate adjuvant because, as Persing said in another patent
(applied for May, 2001, while LYMErix was still on the market, harming
people; he never said anything to the FDA about it):
Prophylactic and therapeutic treatment of infectious and other
diseases with mono- and disaccharide-based compounds
"Accordingly, the methods of the invention provide a powerful and
selective approach for modulating the innate immune response pathways in
animals without giving rise to the toxicities often associated with the
native bacterial components that normally stimulate those pathways."
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/PTO/srchnum.htm&r=1&f=G&l=50&s1=6,800,613.PN.&OS=PN/6,800,613&RS=PN/6,800,613
In this complaint to the UN Human Rights Commission and the foreign
embassies:
http://www.actionlyme.org/EMBASSIES_CORIXA_TLR_13_JULY_06.htm
it shows that Corixa got an 11 million dollar “biodefense contract” from the
NIH and the adjuvants they are allegedly producing are TLR4 agonists, not
TLR2/1 agonists like LYMErix, because Persing et al know OspA as an adjuvant
is “too
toxic in the native form” and "…Additional uncertainty may arise if the
vaccines are not completely protective; vaccinated patients with multisystem
complaints characteristic of later presentations of Lyme disease may be
difficult to distinguish from patients with vaccine failure," which means
they know OspA is too toxic and causes a chronic illness identical to
chronic Lyme.
5) In 1998 Yale’s Robert Schoen wrote the following article in the ALDF’s
book, Lyme
Disease, ACP Key Diseases Series, published in 1998 to coincide with
the release of LYMErix onto the market. Once again. Schoen is paving the
way, instructing other “doctors” to view LYMErix-injured people and Chronic
Lyme victims (which are essentially the same disease, Post-Sepsis Syndrome)
through the same victim-blaming lens.
The article is called Clinical
Vignettes, Case 13, A Vaccine Recipient who Develops Arthralgia and Fatigue, page
238-9, and is about what to do with a person who has had the Yale
dangerous rOspA non-vaccine. He says not to test these LYMErix victims and
he minimizes their symptoms, knowing that late, neurologic chronic Lyme
symptoms are identical to what Schoen says are "nonspecific" (fatigue,
meningitis, etc.; post-sepsis syndrome).
Schoen says the exact reverse in the
Persing-Schoen-Corixa-RICO patent (US. Pat. No. 6,045,804 and associated
journal report, http://www.ncbi.nlm.nih.gov/pubmed/8968914): "multisystem
complaints characteristic of late Lyme," where the two developed the assay
together but only Persing is listed on the patent.
WRITES SCHOEN (you can tell this is BS because it does not make any real
sense):
”QUESTION
”Is this patient’s presentation compatible with Lyme disease?
”COMMENT
This patient presents with nonspecific symptoms, including arthralgias and
fatigue. Although he lives in an area endemic for Lyme disease, these
findings by themselves do not point to Lyme disease.
“The risks of a false-positive serologic test result in this
patient will be significant because the prevalence of Lyme disease in such
individuals is low. More importantly, this patient has already received a
Lyme disease vaccine. Because of this, he will have antibodies against the
31-kd OspA Borrelia burgdorferi protein. These antibodies will be directed
by the Lyme ELISA and will generate a positive test resut.
“In the absence of specific clinical features suggesting a
diagnosis of Lyme disease, the best course of action may be not to do
serologic testing for Lyme disease at all. If such testing is to be done in
a person who has received the Lyme disease vaccine, it will need to be sent
to a laboratory where the Western blot analysis can be done that omits the
31-kd response.”
"CONCLUSION:
"In Lyme disease recipients
(sic), Western blot analysis is indicated to distinguish Lyme disease from
seroconversion caused by vaccination."
Schoen (above) probably means “In Lyme disease vaccine recipients,
Western blot analysis is indicated to distinguish disease from
seroconversion by vaccination.”
This does not make a whole lot of sense because Schoen first said not to
test them, just blow these people off, essentially, because their symptoms
were vague (means, “not a red, swollen knee”). But then Schoen went on to
say that if you MUST test them, use the Persing-Schoen RICO patent method
with the OspA-B plasmid missing, making it very clear
that the reason OspA and B were left out of the Dearborn standard was to
satisfy this subsequent racketeering condition or monopoly on testing, once
LYMErix was on the market. That is why I call this the RICO patent:
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
This transcript of Schoen’s “Clinical Vignettes” above is in that textbook
with the libel and false statements including the Munchausen’s
accusations:
“Lyme Disease, ACP Key Diseases Series, by Rahn and Evans”
ISBN-10:
0-943126-58-4 , ISBN-13: 9780943126586
Publisher: American
College of Physicians
Year: January
15, 1998
http://www.amazon.com/Lyme-Disease-Key-Diseases-Series/dp/0943126584/ref=sr_1_fkmr0_2?ie=UTF8&qid=1341914626&sr=8-2-fkmr0&keywords=lyme+disease+rhan+and+evans
See more at http://www.actionlyme.org/SCHOEN_INSTRUCTING_DOCS_TO_BLOW_OFF_LYMERIX_INJUREES.htm
From start to finish, from when the ALDF.com was established in 1990,… to
Steere going to Europe in 1992 to falsify the case definition antibody panel
and adding the ridiculous ELISA “screening test” (for arthritis only) for a
fungal-like disease, … to the CDC falsifying the testing for Lyme at
Dearborn in 1994, … to lying to the FDA and the journals about their
outcomes of the 2 vaccine trials in 1998, to fake “Guidelines” based on the
bogus Klempner non-retreatment non-study in 2001,…. the point of this scam
was to create a condition where only they –
the CDC staff and the ALDF.com - would be able to capitalize on vector-borne
diseases vaccines and test kits.
They intended to get all the grants, all the royalties, and to define the
diseases based on their fake products.
Most importantly, they wanted this post-:LYMErix monopoly on human blood
testing because they could pharm from that not only human DNA and disease
susceptibilities, but new vector borne disease DNA to patent. It was all
about the money. It was all about cornering the market on this new genre of
potential diseases resulting from global pollution.
========
Falsifying the Vaccine Trial Results, Part 2 of the Cryme – the
Unreadable Western Blots.
The 1998 Vaccines Reports (ImuLyme and LYMErix):
LYMErix results (76% "safe and effective"):
N Engl J Med. 1998
Jul 23;339(4):209-15.
Vaccination against Lyme
disease with recombinant Borrelia
burgdorferi outer-surface lipoprotein
A with adjuvant. Lyme
Disease Vaccine
Study Group.
Steere AC1, Sikand
VK, Meurice
F, Parenti
DL, Fikrig
E, Schoen
RT, Nowakowski
J, Schmid
CH, Laukamp
S, Buscarino
C, Krause
DS.
https://www.ncbi.nlm.nih.gov/pubmed/9673298
http://content.nejm.org/cgi/content/abstract/339/4/209
ImmuLyme results (92% "safe and effective"):
N Engl J Med. 1998
Jul 23;339(4):216-22.
A vaccine consisting of recombinant Borrelia
burgdorferi outer-surface protein A to prevent Lyme
disease. Recombinant Outer-Surface
Protein A Lyme
Disease Vaccine Study
Consortium.
Sigal LH1, Zahradnik
JM, Lavin
P, Patella
SJ, Bryant
G, Haselby
R, Hilton
E, Kunkel
M, Adler-Klein
D, Doherty
T, Evans
J, Molloy
PJ, Seidner
AL, Sabetta
JR, Simon
HJ, Klempner
MS, Mays
J, Marks
D, Malawista
SE.
https://www.ncbi.nlm.nih.gov/pubmed/9673299
http://content.nejm.org/cgi/content/abstract/339/4/216
From the LYMErix trial, "categories of outcomes:"
http://content.nejm.org/cgi/content-nw/full/339/4/209/T1
YET, here are the Cabal claiming "we can't read our OspA vaccine results"
reports, which means they lied in their OspA vaccine safety and efficacy
reports, since they both claimed to be using the Dearborn method and MarDx's
Western Blot test strips:
Clin Infect Dis. 2000
Jul;31(1):42-7. Epub 2000 Jul 17.
Detection of multiple reactive protein species by
immunoblotting after recombinant outer surface protein A lyme disease
vaccination.
Molloy PJ1, Berardi
VP, Persing DH, Sigal LH.
“…The
manufacturer of the only currently FDA-approved (and released) recombinant
OspA Lyme disease vaccine has suggested that vaccination does not interfere
with serological evaluation of Lyme disease in vaccine recipients—a
statement that is not supported by the data presented here.”
https://www.ncbi.nlm.nih.gov/pubmed/10913394
https://academic.oup.com/cid/article-lookup/doi/10.1086/313920
Yale’s Robert Schoen and Mayo’s/Corixa’s David Persing, with John
Anderson,1995-6; the RICO within the RICO report whch shows the intended
monopoly on post-LYMErix testing for vector borne diseases (for Yale, Imugen
and Corixa, officially “partners” listed on the SEC):
J Clin Microbiol. 1997
Jan;35(1):233-8.
Borrelia burgdorferi enzyme-linked
immunosorbent assay for discrimination of OspA vaccination from spirochete
infection.
Zhang YQ1, Mathiesen
D, Kolbert
CP, Anderson
J, Schoen
RT, Fikrig
E, Persing
DH.
https://www.ncbi.nlm.nih.gov/pubmed/8968914
http://jcm.asm.org/cgi/reprint/35/1/233?view=long&pmid=8968914
Same: Schoen and Persing in their 1995-6 RICO method patent:
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
In this patent,
they state:
”…
Additional uncertainty may
arise if the vaccines are not completely protective; vaccinated patients
with multisystem complaints characteristic of later presentations of Lyme
disease may be difficult to distinguish from patients with vaccine failure.
Vaccine failures have been occasionally noted in animal models (E. Fikrig et
al., Science, 250, 553-6 (1990)), and infection with antigenically variant
strains of B. burgdorferi, which are being increasingly documented in the
U.S., might still occur.”
They state that they cant tell the difference between Lyme and LYMErix
disease, they’re both multi-system diseases (post-sepsis).
Yale's Robert Schoen, as you’ve seen previously in “Clinical Vignettes”
above, in the 1998 Munchausen's Book, instructed MDs to blow off
LYMErix-systemically-injured people ("but send the post-vaccination blood to
the Yale L2 Diagnostics RICO lab if you must bother to be a physician").
They used the bogus Dearborn method, reported that they had “safe and
effective vaccines,” did not report that their Western Blots were
unreadable. Which means they had NO vaccines, and also
reported in their patents that the vaccines caused a disease identical to
“multisystem” Lyme. Each vaccine trial report and summary was 3 false
claims. Not
safe, and not effective, and the Dearborn case definition was false and not
even a consensus.
====
In the fall of 1998, the LYMErix vaccine was approved by the FDA, anyway
(the FDA panel being loaded with people like Allen Steere, Robert Schoen,
and Vijay Sikand – the very people who ran the OspA trials). It came onto
the market in late 1998 “despite numerous provisos.”
More than 1,000 systemic adverse events were reported
through the VAERS from September 1999 to November 2000, whereupon the FDA
granted a public hearing, January 31,
2001: http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2.htm
Whereupon, the whistle was blown on Dearborn and how
LYMErix actually caused immunosuppression (the FDA did not scan in the last
19 pages of this booklet, which were 19 pages out of the Dearborn booklet,
proving no one agreed with Steere's proposal for an antibody panel for a
"case definition"):
http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2_11.pdf
Several months later, in the fall of 2001, Karen Forschner of the Hartford,
CT based Lyme Disease Foundation (Lyme.org) delivered to the FDA – in
person, a patent owned by Brigitte Huber at Tufts University, where it was
declared that OspA was technically a “toxin,” right in the abstract (US
Patent 6,689,384). The FDA then gave SmithKline and Yale, the assignee of
the LYMErix patent, an ultimatum that said essentially this: “Either you
remove LYMErix voluntarily or we will order it off the market.” SmithKline
chose to avoid the embarrassment and pulled their own non-vaccine off the
market.
We’re still stuck with this bogus Dearborn case definition, despite numerous
attempts at lawsuits against IDSA, SmithKline, and filing complaints to the
U. S. Department of Justice. It is still very dangerous for the public to be
unaware that the average person, or 85% of us – who are the "seronegative
patients are the sickest," have no chance of testing positive to this
criminal CDC-Dearborn standard, because the actual disease is one of
immunosuppression, or is an Acquired Immune Deficiency, or is similar to
AIDS with all the opportunistic viral infections and lymphocyte mutations
that can’t be treated with antibiotics, alone.
It was said at the time LYMErix was still on the market that this vaccine,
via its claimed mechanism of disinfecting ticks with human antibodies (yes,
if you can believe it), that LYMErix would turn humans into walking
canisters of tick disinfectant, when in fact, LYMErix turned people into
walking “cesspools of disease.” The same is true for Chronic Lyme. Chronic
Lyme victims’ immune systems are “overwhelmed”- a term used by CDC officer
Alan Barbour, when describing what antigenic variation in spirochetes does
to humans (US Patent 6,719,983). This is a term you want to remember in case
you hear it again: “overwhelmed” immune system means: “turned off.” “Turned
off” is the complete opposite of an “inflammatory” or “autoimmune disease.”
